AstraZeneca's revenue from vaccines in the second quarter was $894 million

Vaccine maker AstraZeneca has announced second-quarter revenue. The company's revenue from vaccines in the second quarter of the year was 894 million.

image

AstraZeneca's revenue from vaccines in the second quarter was $894 million
AstraZeneca's corona virus vaccine sales revenues tripled from the previous month to $894 million in the second quarter, but the company again delayed its application for vaccine approval in the US as it continued to collect more data.

The AstraZeneca vaccine was seen as an important weapon against the epidemic because it was cheaper and easier to use. AstraZeneca and its India-based manufacturing partner announced that they have delivered 1 billion doses of vaccine to 170 countries so far.